BIOMUS - Live Now

Precision Medicine:
Redefining the Future of Healthcare

October, 2026 | San Francisco, CA

BIOMUS - Look Back

Biomarkers & Precision Medicine US 2025

Thank you for attending!

From beginning to end, Biomarkers & Precision Medicine US 2025 showcased the dedication to advancing personalized healthcare within our community.

We hope you leave with new connections, fresh perspectives, and valuable takeaways from the sessions on Biomarkers, Spatial Biology, and Digital Pathology & AI.

Thank you again for joining the conversation. We look forward to seeing the incredible impact you'll make in the world of precision medicine!

Programme Image 4

Lights, Camera, Action!

Explore our curated photo gallery of standout moments from Biomarkers & Precision Medicine US 2025. See if you can spot yourself!

Lights, Camera, Action!

Explore our curated photo gallery of standout moments from NextGen Omics & Spatial Biology US 2025. See if you can spot yourself!

NextGen Biomed 2025

Advancing Therapeutic Innovation Through Multi-Omics Research  

NextGen Omics & Spatial Biology connects thought leaders, researchers, and experts with pharmaceutical & biotech representatives to discuss the latest innovations across the fields of multi-omics. 

There are three dedicated programmes running across two full days, which together will explore multi-omics from technological development to therapeutic applications and analysis, making this a must-attend event for anyone working in clinical diagnostics, single cell & spatial biology. 

Hear from past attendees of last year's Biologics 2024 conference

Explore the NextGen Omics & Spatial Biology US 2025 Programme

Antibody Society

NextGen Biomed 2025 is supported by our
Scientific Programme Partner The Antibody Society

Key Themes

Experts agree: the future of precision medicine lies in layering multi-omics with cutting-edge technologies.

Spatial transcriptomics unlocks a treasure trove of archived samples, accelerating drug discovery, early detection, and patient stratification. Advances in sensitivity and throughput are driving progress, while multiplex assays edge closer to clinical use as companion diagnostics. Targeted protein degradation is emerging as a powerful tool, offering precision with reduced toxicity. New single-cell analysis methods are revealing molecular insights in patient settings, bridging research and real-world impact.

The challenge now? Integrating these breakthroughs to truly deliver on the promise of precision medicine.

Key Event Highlights

An unmissable journey awaits you: From celebrated keynote speakers and insightful fireside chats, to the brand new Awards Dinner. Discover the moments that will transform your Biomarkers & Precision Medicine experience. 

What's been happening at NextGen Omics & Spatial Biology US 2025?

Have a peek into the dynamic panels, engaging roundtables, and hands-on workshops happening in Boston - right now!

spatial biology Track keynote address 
 Spatial Multi-Omics For Target-To-Disease Linkage In Inflammatory Diseases

MARINA BLECK, Principal Scientist, Boehringer Ingelheim

Marina discussed the use of multi omics for faster Faster Target-to- Disease Link (T2DL) with increased confidence and how they can leverage Spatial Biology to enhance the ability to derive insight from human disease tissues.  Finally the Importance of FFPE Tissue Quality for Spatial Biology was discussed with the use of QC scoring to determine which FFPE tissue gives the best spatial transcriptomics results.

spatial biology day one, track 6 
Spatial Biology As A Discovery Pathway

EMRE ARSLAN, Takeda

Emre Arslan from Takeda gave a talk about the use of Spatial Biology as a discovery pathway. First of all providing an update on the current landscape for spatial technologies then analysing how spatial technologies can be used in clinical trial design - such as the ability to identify previously unknown cell types, interactions and microenvironments and providing an ideal foundation for training better AI models. 

day 2 keynote
Single Cell into Spatial and Beyond: Landscape in 2025 and What’s Next?

JASMINE PLUMMER, Director, St Jude Children's Research Hosptial

Jasmine Plummer's day 2 keynote focused on Single cell into spatial and beyond.  "The reason we are in this room is because it’s cutting edge" which is why the single cell and spatial field growing exponentially.

Future directions for the technology include Low throughput, clinical trials, other organisms, more tissue types, epigenomics

Spatial multi-omics, track 4 Keynote
Rapid Single-Cell Spatial Proteomics by Spatial MIST

JUN WANG, Associate Professor, Multiplex Biotechnology Laboratory, Department of Biomedical Engineering, Stony Brook University

"Simpler but more powerful than flow and imaging cytometry"

MIST Technology provides100 times more information than flow cytometry and currently the highest multiplexity is up to 500 markers/ cell.

Single cell track keynote address
Panel Application Of Single Cell Omics In Clinical Monitoring

PRIYA CHOCKALINGAM, Vice President, Head of Clinical BioAnalytics & Translational Sciences, Beam Therapeutics

Priya's talk focused on Genome Editing Technologies for Gene & Cell Therapy and how cell & gene therapies require a specialized regulatory approach compared to other modalities. Appropriate assessments should therefore be put in place in both nonclinical and clinical stages to address safety concerns.

Various methods to assess off-target editing effects have evolved in the last decade. However, limitations remain in balancing accuracy vs sensitivity of these new techniques.

The direct assessment of off-target effects in vivo and in patients is particularly challenging.

Novel single-cell technologies enable quantitation/co-occurrence of on-/off-target editing through patient time-course of treatment

single cell  
Comparative Insights In Single Cell RNA-seq & Advances In Large-Scale Multimodal Profiling

ZORA MODRUSAN, Senior Director NGS, Genentech

Zora focused on both key insights and future directions of single cell RNA-Seq.  scRNA-seq technologies were evaluated and the differences in performance across various metrics such as sensitivity, throughput and cost were compared across different systems.

The Overloading And unpacKing (OAK) method provides a reliable solution for large-scale molecular profiling that incorporates multiple data modalities.

Moving forward they will continue to evaluate the latest scRNA-seq kits to understand differences and guide optimal performance. Zora would also like to enhance OAK's capabilities by integrating additional modalities and applying the platform to a wide range of biological systems.

Key Event Highlights

An unmissable journey awaits you: from celebrated keynote speakers and insightful private roundtables, to an exclusive gala dinner. Discover the moments that will transform your NextGen Omics & Spatial experience. 

Meet Our Expert Speakers

The event brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data, and industry outlooks. Below were some of the featured speakers at Biomarkers, CDx & Precision Medicine US 2025: 27 - 28 October 2025, San Francisco, CA, USA

Abhishek Aggarwal
Director, Pathobiology,
Gilead Sciences
Alexander Klimowicz
Principal Scientist,
Boehringer Ingelheim
Anil Sood
Professor, Vice Chair for Translational Research & Co-Director of the Center for RNA Interference and Non-Coding,
Anderson Cancer Center
David Weingeist
Scientific Director,
Johnson & Johnson
Elsa Flores
Associate Center Director,
Moffitt Cancer Center
Ida Sim
Director,
University of California San Francisco
Lee Hood
Chief Executive Officer,
Phenome Health
Mike Montalto
Vice President,
Amgen
Suzanne Coberly
Scientific Senior Director, Translational Pathology,
BMS
Abeer Obaid
Senior scientist,
Abbvie
Amrita Pati
Executive Director,
Amgen
Amy Delson
Research Advocate,
UCSF Breast Science Advocacy Core
Anuraag Shrivastav
Professor,
University of Winnipeg
Danielle Tan
Senior Scientist l,
BioMarin Pharmaceutical
Diane Stephenson
Vice President, Neurology; Executive Director, Critical Path for Parkinson’s,
Critical Path Institute
Elizabeth Hillman
Chair, Imaging Sciences,
St Jude Children's Research Hospital
Evan Keller
Professor,
University of Michigan
Fangyao Hu
Senior Principal Scientist,
Genentech
Gerald Quon
Associate Professor,
University of California
Guneet Walia
S,
JNJ
Hongda Zhao
Director,
Bristol Myers Squibb
I-Ming Wang
Director, Translational Oncology,
Pfizer
Jack Chen
Scientific Director, Translational Oncology, Precision Medicine,
AbbVie
Jan Schejbal
Senior Scientist,
AbbVie
Jan Tomlinson
Research Advocate,
I-Spy Trial
Jana Lipkova
Assistant Professor, Department of Pathology and Molecular Medicine,
University of California, Irvine
Janet Jin
Executive Director,
Amgen
John Snowball
Scientist,
P&G
Joshua Levy
Director,
Cedars-Sinai
Koichi Hashikawa
Principal Computational Scientist,
Johnson & Johnson Innovative Medicine
Laurent Audoly
Chief Executive Officer,
PriveBio
Mark Magbanua
Laboratory Medicine,
University of California San Francisco
Melanie Sobri
Administrative Assistant,
UCLA
Mike Washburn
Executive Director,
GSK
Natália Murad
Bioinformatics Specialist,
University of California
Neil Pfister
Assistant Professor,
University of Alabama at Birmingham
Nicole Davis
Associate Director, Bioanalytical & Biomarker Development,
Ultragenyx
Olivier Harismendy
Vice President,
Zentalis Pharmaceuticals
Samir M. Hanash
Director,
MD Anderson Cancer Center
Satya Saxena
Director,
Eisai
Sergey Novitskiy
PS,
Amgen
Sudeshna Fisch
Director,
Pfizer
Susmita Datta
Professor,
Department of Biostatistics, University of Florida
Tammie Yeh
Senior Director,
Takeda
Vicki Plaks
Senior Scientific Director,
Johnson & Johnson
Vidarshi Muthukumarana
Assistant Professor, Program Director, Surgical Pathology Fellowship Program, University of Texas Medical Branch – Galveston,
UTMB
Vladimir Roudko
Director, Advanced of Translational Programs,
AstraZeneca
W. Dean Wallace
Professor,
University of Southern California
Yasser Riazalhosseini
Associate Professor,
McGill University
Yesim Gokmen-Polar
Associate Professor, Pathology Cancer Program,
Emory University School of Mediicne
Zheng Ao
Principal Scientist, Cell Therapy,
Obsidian Therapeutics
Zoltan Laszik
Director,
University of California San Francisco

Interested in Sponsoring NextGen Omics & Spatial Biology US 2025?

Become a driving force in accelerating the next generation of multi-omics-based treatments. NextGen Omics & Spatial Biology US offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of genomic medicine today.

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Interested in Sponsoring Biomarkers, CDx & Precision Medicine US 2026?

Become a driving force in accelerating the next generation of personalized treatments. Biomarkers, CDx & Precision Medicine US 2026 offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, & academic experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, & collaborate with the community shaping the future of precision medicine today.

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The NextGen Biomed Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist.

Please submit your poster presentation by no later than 13th January 2025 in the below category:

  • Protein/Antibody Engineering
  • Bioanalysis & Characterisation
  • Next Generation Biotherapeutics
  • Peptides Chemistry & Therapeutics
  • Oligonucleotides Chemistry & Therapeutics
  • Sustainable Chemistry & Manufacturing
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 13th January 2025
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 13th January 2025 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the NextGen Biomed series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

Interested in Biomarkers, CDx & Precision Medicine US 2026?